OR4C11

Across TCGA pan-cancer cohorts, OR4C11 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR4C11 data layer compared with 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher OR4C11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR4C11 expression acts as an unfavorable survival marker.

BRCA, ESCA, and ACC are the cancer types where OR4C11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.595	0.924	<.001	29	view →
ESCA	OS	Median	II,III,IV	0.162	0.707	<.001	24	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
LUAD	OS	Median	II,III,IV	0.111	0.750	<.001	12	view →
LIHC	DFS	Median	All	0.171	0.545	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OR4C11–BRCA (OS)

Open the BRCA breakdown →